Vaccine deals: India, Oxford-AstraZeneca numbers dip, but still on top; Pfizer gains most
Analysis of contracts countries are signing with vaccine makers for
advance booking of candidates shows that the deals are still fluid,
changing in a matter of days with some companies gaining and some
losing orders given that most candidates are still in trial stage.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/vaccine-deals-india-oxford-astrazeneca-numbers-dip-but-still-on-top-pfizer-gains-most/articleshow/79714788.cms
advance booking of candidates shows that the deals are still fluid,
changing in a matter of days with some companies gaining and some
losing orders given that most candidates are still in trial stage.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/vaccine-deals-india-oxford-astrazeneca-numbers-dip-but-still-on-top-pfizer-gains-most/articleshow/79714788.cms
Comments
Post a Comment